You searched for: oxcia

Oxcia's substances show antiviral activity

Oxcia also receives ODD approval from EMA

Earlier this spring, Oxcia announced that the drug candidate OXC-101 had received Orphan Drug Designation (ODD) from the US Food and Drug Administration (FDA) for...

Oxcia enters into dermatology collaboration agreement with LEO Pharma

Oxcia is taking a strategic step to broaden the scope of its drug candidate OXC-101 by entering into a research collaboration with the...

Oxcia | Global Forum 2025

CEO Ulrika Warpman Berglund presents Oxcia at BioStock Global Forum 2025.

Oxcia receives ODD from FDA – CEO comments

Oxcia has received Orphan Drug Designation from the FDA for OXC-101 as a treatment for acute myeloid leukemia (AML), the most common...

Psoriasis – new opportunity for Oxcia

Oxcia has so far focused on treating cancer with its drug candidate OXC-101. Now the company sees a promising opportunity to...

Thomas Helleday and Oxcia in the fight against cancer and inflammation

The founder and largest owner of the biotechnology company Oxcia, Thomas Helleday, is known for his research and development of new treatment strategies against...

Another successful Summit – see all videos here

On November 20-21, we invited you to the BioStock Life Science Summit for the seventh time and now you can see...

Oxcia's CEO on the focus on AML and pulmonary fibrosis

Oxcia is now focusing wholeheartedly on the development of its lead candidate OXC-101 against the aggressive blood cancer AML, in parallel with preclinical development...